By Julia Karow

As second-generation sequencing platforms have matured, all three major high-throughput sequencing systems — Illumina's Genome Analyzer, Life Technologies' ABI SOLiD, and Roche's 454 GS FLX — have entered labs across the world, according to a recent survey by In Sequence.

Although two-thirds of the 50 labs polled in the survey own only a single type of next-gen sequencing platform, a number of centers have started to mix and match systems from different vendors.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.